Navigation Links
Frost & Sullivan Recognizes ResearchDx for Its Impressive Performance in the Companion Diagnostics Sector
Date:2/11/2013

IRVINE, Calif., Feb. 11, 2013 /PRNewswire/ -- Based on its recent analysis of the companion diagnostics market, Frost & Sullivan recognizes ResearchDx with the 2012 North American Frost & Sullivan Award for Entrepreneurial Company of the Year. In an industry where the trend in the contract services sector is moving toward greater specialization and focusing on a few key capabilities, ResearchDx's mission to be a sole provider and affordable option for contract diagnostic development is both unique and entrepreneurial.

"ResearchDx originated the concept of a contract diagnostic organization for biopharmaceutical companies and diagnostic companies, which is analogous to the services a contract research organization would provide for drug clinical trials," observed Frost & Sullivan Senior Industry Analyst Winny Tan . "The company can provide contract R&D across the entire development and commercialization process for companion diagnostics for pharmaceutical companies, in vitro diagnostic (IVD) companies and clinical laboratories, strongly positioning it at a critical time in the market for impressive and sustainable growth over the long term."

ResearchDx provides services including assay development, validation, and optimization for a clinical setting; study management and regulatory submissions; validation of laboratory-developed tests; test deployment in its Clinical Laboratory Improvement Act (CLIA) and College of American Pathologists (CAP) accredited laboratory; and in vitro diagnostic (IVD) kit manufacturing in its good manufacturing practice (GMP) facility.

ResearchDx's strategy has proved to be a winning one; the early stage company has achieved 150 percent annual revenue growth consistently for the past three years. As the first fully integrated contract diagnostic organization, the company is an extremely valuable partner for accelerating the regulatory approval and commercialization of diagnostic products.

"ResearchDx leads in delivering customer value, because customers receive the best solution that is matched to their specific needs," explained Tan. "Further, the company leverages more than 20 years of clinical diagnostic laboratory industry experience to offer expert advice. Unlike many of its competitors that offer diagnostic development limited to their proprietary platforms, ResearchDx's solutions are driven by the customer's diagnostic needs, rather than any one diagnostic platform."

For its extraordinary performance in the contract diagnostics organization sector, Frost & Sullivan recognizes ResearchDx as the 2012 North American Entrepreneurial Company of the Year Award recipient.

Each year, Frost & Sullivan presents this award to the company that has demonstrated entrepreneurial spirit by devising a strong growth strategy and robustly implementing it. The recipient has shown strength in terms of innovation in business processes, leadership in customer value as well as market penetration. In short, the award looks at the emerging market players in the industry and recognizes their best practices that are positioned for future growth excellence.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About ResearchDx

ResearchDx is The Contract Diagnostics Organization (CDO) for the biopharmaceutical and diagnostic industries. The company provides comprehensive, integrated, flexible services for the in vitro diagnostic development process. From initial assay conceptualization, discovery, optimization and validation in a CAP/CLIA laboratory environment, through a complete set of clinical research services and on to regulatory approval, ResearchDx offers the services and solutions to meet complex diagnostics development needs.   ResearchDx's primary service areas include assay research and development, clinical laboratory services, clinical research, diagnostic manufacturing, and consulting.  Additional information is available at www.researchdx.com.  

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:        Gain access to visionary innovation

Contact:

Mireya Espinoza    
P: 210. 247.3870    
F: 210.348.1003    
E: mireya.espinoza@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Gains from a Growing Patient Pool for Cardiac Rhythm Management Devices Offset by Lower Product Pricing, Observes Frost & Sullivan
2. Frost & Sullivan Determines a Real and Urgent Need for Novel Cancer Diagnostics Tests
3. Best Practices Involving Product Innovation and Creation of Value Vital for Customer Retention, Finds Frost & Sullivan
4. Contract Research Organisations offer Promise of Innovative, Safe and Effective Drug Development, Says Frost & Sullivan
5. Medical Devices 2013: A Frost & Sullivan Executive MindXchange- Sustaining the Vitality of the Industry and Your Company
6. Proposed Regulatory Uniformity to Boost Venture Capital Investments in Healthcare Arena, Says Frost & Sullivan
7. Americas Interest in Obesity Surgery Soars Following its Success in Europe and ROW, Finds Frost & Sullivan
8. Advances in Cosmesis Increase Amputee Acceptance of Prosthesis and Orthotics Devices, Finds Frost & Sullivan
9. Increasing Prevalence of Heart Disease Drives Growth of Cardiac Biomarkers Diagnostics Market, Says Frost & Sullivan
10. Frost & Sullivan: Appropriate Channel Partners Vital in the Highly Fragmented Medical Devices Distribution Market in VITSK
11. Frost & Sullivan: TNF Inhibitors Lay the Groundwork for the Next Generation of Disease-Modifying Anti-Rheumatic Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... The OSHA Training Center at Chabot-Las ... headquartered in Northern California, has issued an important reminder to employers to prevent ... Employers with workers exposed to high temperatures should establish a complete heat illness ...
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced today its affiliation with Tennessee Counseling Association. This new relationship ... of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA ...
(Date:6/27/2016)... , ... June 27, 2016 ... ... the patient payment industry today announced its strategic partnership with Connance, a ... workflows. , The two companies’ proven, proprietary technology combine to provide health ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
Breaking Medicine News(10 mins):